NETRI launches NeuroFluidics MEA line in collaboration with Axion BioSystems
High-throughput organs-on-chip platforms for disease research and drug discovery in neurology and dermatology
31 Jul 2023NETRI has announced the commercial launch of its NeuroFluidics™ MEA line, developed in collaboration with Axion BioSystems and compatible with the company’s flagship Maestro MultiElectrode Array (MEA) systems. The new product line offers a range of ready-to-use compartmentalized microfluidic devices with an integrated MEA layer, providing high-throughput organs-on-chip platforms for disease research and drug discovery in neurology, dermatology, and other fields.
Due to their ability to recapitulate key aspects of human physiology in vitro, organs-on-chips are relevant models for biomedical research applications — but developing these advanced models has been challenging for individual labs until now. According to NETRI CEO Thibault Honegger, the new NeuroFluidics MEA line bridges that gap, “Following a successful beta testing phase, we are incredibly proud to unveil this new and unique standardized in vitro platform that achieves the fusion of electrophysiology and microfluidics. This disruptive technology represents a substantial advance in the world of neuroscience by providing a new breed of highly relevant and repeatable datasets.”
The pairing of NETRI’s advanced neuro-organs-on-chips devices with Axion’s Maestro MEA benchtop systems has the potential to accelerate drug development for Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, sensitive skin, peripheral neuropathic pain, gut-brain axis and other conditions. “The synergy between NETRI’s high-throughput compartmentalized microfluidics devices and Axion’s MEA technology is an exciting new frontier for our customers,” said Kevin Gould, Axion BioSystems’ CEO. “We expect these new MEA plates will help accelerate our understanding of neurological disorders and the development of new therapies.”